Arcus Biosciences
RCUS
RCUS
185 hedge funds and large institutions have $1.02B invested in Arcus Biosciences in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 68 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 68
1% less funds holding
Funds holding: 187 → 185 (-2)
Holders
185
Holding in Top 10
3
Calls
$14.5M
Puts
$7.25M
Top Buyers
| 1 | +$15.2M | |
| 2 | +$14.6M | |
| 3 | +$7.95M | |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$6.88M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$6.21M |
Top Sellers
| 1 | -$25.2M | |
| 2 | -$7.75M | |
| 3 | -$6.31M | |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.31M |
| 5 |
Barclays
London,
United Kingdom
|
-$5.12M |